Aug 3, 2026 08:30AM
Aug 3, 2026 08:30AM
Jul 21, 2026 08:03AM
Jul 21, 2026 08:00AM
Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM
Jun 30, 2026 08:00PM Cadrenal Therapeutics launches up to $8.8M private placement
Jun 30, 2026 08:00PM
Jun 24, 2026 08:01AM
Jun 24, 2026 08:00AM
Jun 18, 2026 09:01AM
Jun 18, 2026 09:00AM
Jun 15, 2026 08:30AM
Jun 15, 2026 08:30AM Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM
May 19, 2026 04:30PM
May 7, 2026 08:30AM
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:30AM Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM
Mar 12, 2026 08:00AM
Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM
Aug 6, 2024 09:00AM
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM
Jun 3, 2024 09:00AM Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
May 23, 2024 09:00AM

328,347 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All